Lucid Diagnostics to Participate in Upcoming Investor Conferences
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM), has announced its participation in two upcoming investor conferences in August 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM), has announced its participation in two upcoming investor conferences in August 2025.
The company will attend the 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference for one-on-one meetings on August 11-12, 2025. Additionally, management will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 2:30 PM ET in Boston, MA. The Canaccord presentation will be available via webcast with a 30-day replay option.
Details
News Market Reaction – LUCD
On Aug 5, the day this news came out, LUCD closed 1.96% below the previous close.
Data tracked by StockTitan Argus for the Aug 5 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
- 1x1 Meetings: August 11-12, 2025
- Location: Virtual
- Canaccord Genuity 45th Annual Growth Conference
- Fireside Chat: August 13, 2025, at 2:30 PM ET
- Location:
Boston, MA
The live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking here or by visiting the Investor Relations Section of the Lucid Diagnostics website. A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-participate-in-upcoming-investor-conferences-302521811.html
SOURCE Lucid Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.